...Céline Sergeant; Joseph Kerger; Annie Drowart; François Sales; Mireille Langouo Cutaneous melanoma can metastasize to almost any organ, including in-transit metastases, lymph nodes, liver, lungs, brain, and bones. Spread to the gastrointestinal tract is less common and generally concerns the small...

...Hiroshi Kato; Shinji Kano; Yukiko Yasui; Yuka Nojiri; Maki Yoshimitsu; Motoki Nakamura; Akimichi Morita The most important driver gene in malignant melanoma is the BRAF mutation, and molecularly targeted therapies targeting mutations, mainly V600E and V600k, are used in clinical practice...

...Kentaro Ohuchi; Ryo Amagai; Yumi Kambayashi; Yoshihide Asano; Taku Fujimura Advanced melanoma patients with liver metastases show a limited response to immunotherapy by the induction of regulatory T cells and depletion of effector cells, which leads to a poor prognosis. Tumor-associated macrophages...

...Kenta Nakamura; Hiroshi Koga; Yuko Takazawa; Toshikazu Omodaka; Yukiko Kiniwa; Ryuhei Okuyama In this report, we present a case of cardiac metastasis of a malignant melanoma originating from the nasal cavity and presenting with cardiac tamponade detected during immunotherapy. The patient was a 66...

...Maria Chiara Tronconi; Arianna Marinello; Alessandra Solferino; Susanna Grimaudo; Michele Ciccarelli; Sofia Manara; Luca Cozzaglio; Luca Mancini; Riccardo Borroni; Armando Santoro BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) exert a cytotoxic and immune-mediated effect on metastatic melanoma...

...Yumi Kambayashi; Kentaro Ohuchi; Hiromu Chiba; Erika Tamabuchi; Tasuku Nagasawa; Yoshihide Asano; Taku Fujimura Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than...

...Kohei Fujita; Koichi Nakatani; Takuma Imakita; Osamu Kanai; Tadashi Mio Malignant melanoma is a rare and high-grade cancer. It most commonly affects the skin, but it has the potential to involve all areas of the body. Primary pulmonary malignant melanoma is rare, accounting for only 0.01% of all...

... transformation, the most common histologies are sarcomas and primitive neuroectodermal tumours; however, other subtypes have been recognized including melanoma, leukaemia, and renal cell carcinoma. We report a case of a 38-year-old male who had recently completed treatment for a mediastinal germ cell tumour...

...-related adverse events Pancreatic insufficiency Nivolumab Immunotherapy Melanoma The use of immunotherapy for the treatment of various malignancies is increasingly gaining applicability. While the 5-year survival rate of patients with metastatic melanoma was only 15% prior to the introduction...

...Panagiotis Gouveris; Dionysia N. Zouki; Evangelos G. Sarris; Likourgos Kolilekas; Dimitrios Tryfonopoulos; George Papaxoinis; Stamatina Demiri Sarcoidosis and sarcoid-like reactions have been associated with many solid tumors including malignant melanoma. There are reports of melanoma patients who...

...Diogo Garcia; Juliana Rodrigues Beal; Daniel Mamere Alvarez; Ricardo Silvestre e Silva Macarenco; Gustavo Schvartsman Immune checkpoint inhibitors (ICI) have drastically changed the landscape of metastatic melanoma management, thus significantly improving survival. Clinically, assessing treatment...

... toxicity is one of the most frequent adverse events. In this article, we report a case of anti-PD-1 induced late bullous pemphigoid (BP) with mucosal erosions and associated with a troublesome neurological disorder of undetermined origin in a patient with metastatic melanoma. Skin biopsy was essential...

...Polona Gams; Zvezdana Dolenc Stražar; Maja Šoštarič; Matic Bošnjak; Juš Kšela Cardiac tumors are rare, and their treatment differs interindividually regarding the histopathological proprieties and the stage of disease. Authors present a case of symptomatic cardiac melanoma metastasis that expressed...

...Omar Jiménez-Zarazúa; Lourdes Noemí Vélez-Ramírez; María Alcocer-León; Diego Armando Hernández-Domínguez; Juana Elizabeth Tadeo-González; María Andrea Martínez-Rivera; Martín Daniel Alejandro López-González; Sandra Xaviera Lizeth Tafoya-Rojas; Jaime Daniel Mondragón Melanoma metastasis from...

...Walid Shalata; Nir Peled; Itzhak Gabizon; Omar Abu Saleh; Waleed Kian; Alexander Yakobson In the present case report, we aimed to describe 2 cases of myocarditis occurring as serious adverse effects of immune checkpoint inhibitors (ICIs) administered as treatment for metastatic melanoma. We...

...Sivraj Muralikrishnan; Lara K. Ronan; Shodeinde Coker; Paula K. Rauschkolb; Keisuke Shirai Immunotherapy has improved outcomes in many malignancies, most notably in melanoma, lung cancer, and bladder cancer. Understanding the side effects associated with these medications is an important part...

...Sara Bjursten; Christoffer Vannas; Stefan Filges; Florian Puls; Ankur Pandita; Henrik Fagman; Anders Ståhlberg; Max Levin Approximately 50% of patients with metastatic melanoma harbor an activating BRAF mutation. Tumors with activating mutation BRAF gene proliferate excessively and can be treated...

... effects – so-called immune-related adverse events (irAEs). We present the case report of a 56 year old patient with disseminated melanoma. During treatment with immunotherapy (anti PD-1), neutropenic fever and pancytopenia occurred. Trepanobiopsy of the bone marrow was performed to determine the cause...

... testing in 1872 consecutive melanoma patients. BRAF mutation was identified in 1,090 (58.2%) cases. While drug-sensitive codon 600 substitutions constituted the majority of BRAF gene lesions (V600E: 962 [51.4%]; V600K: 86 [4.6%]; V600R: 17 [0.9%]), the fourth common BRAF allele was K601E accounting for 9...

...Kristina V. Orlova; Grigory A. Yanus; Svetlana N. Aleksakhina; Aigul R. Venina; Aglaya G. Iyevleva; Lev V. Demidov; Evgeny N. Imyanitov Approximately 15% of acral and mucous melanomas carry activating mutations in KIT oncogene. There is a diversity of spectrum of KIT mutations, with some of them...